Log In
Print
BCIQ
Print
Print this Print this
 

Azedra (Ultratrace I-131-MIBG, Ultratrace iobenguane I 131)

  Manage Alerts
Collapse Summary General Information
Company Progenics Pharmaceuticals Inc.
DescriptionRadiolabeled norepinephrine analog
Molecular Target Norepinephrine transporter
Mechanism of ActionRadiolabelled protein
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationNeuroendocrine tumors
Indication DetailsTreat iobenguane-avid metastatic or recurrent pheochromocytoma and paraganglioma; Treat malignant relapsed/refractory pheochromocytoma; Treat neuroendocrine tumors; Treat pheochromocytoma; Treat refractory high-risk neuroblastoma
Regulatory Designation U.S. - Breakthrough Therapy (Treat iobenguane-avid metastatic or recurrent pheochromocytoma and paraganglioma);
U.S. - Fast Track (Treat neuroendocrine tumors);
U.S. - Orphan Drug (Treat neuroendocrine tumors);
U.S. - Special Protocol Assessment (Treat malignant relapsed/refractory pheochromocytoma)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$105.9M

0

$93.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today